萊姆病：市場展望、流行病學、競爭格局、市場預測報告（2025-2035年）

市場概覽

• 法國萊姆病市場預計將從 2025 年的 7,000 萬美元成長到 2035 年的 1.6 億美元。
• 以下因素正在推動市場成長：
• 人們對疾病的認知不斷提高，診斷測試的準確性也日益提高。
• 持續研發新的抗感染疾病療法和疫苗
• 未來的成長取決於早期診斷、預防策略和更有效治療方法的進步。

萊姆病概述

萊姆病由伯氏疏螺旋體引起，透過硬蜱叮咬傳播，仍然是北美和歐洲最常見的蟲媒傳染病，其發生率因氣候變遷導致蜱蟲棲息地擴張而不斷上升。診斷主要依據臨床症狀和兩階段血清學檢測，早期通常可用強力黴素或阿莫西林治癒。然而，延誤治療可能導致涉及神經系統、心臟和關節的併發症，損害身體機能，而萊姆病治療後症候群的症狀仍不甚明了。輝瑞和Valneva的候選疫苗PF-07307405（LB6V，原名VLA15）在2026年3月宣布的3期VALOR試驗中顯示出73-75%的有效率。該疫苗計劃於今年向FDA和EMA提交批准申請，預計將成為自2002年LYMErix停產以來首個預防性疫苗，從而帶來顯著的商業性成長。

主要亮點

• 根據預測，德國萊姆病新發病例數將從 2025 年的 56,330 例增加到 2035 年的 57,357 例。
• 萊姆病是蜱蟲傳播的最常見細菌感染疾病，早期診斷對於預防長期併發症至關重要。
• 延遲治療或治療不足會導致持續的神經系統、心臟和肌肉骨骼症狀。
• 對於頑固性或難治性疾病，仍然迫切需要更好的診斷和治療方法。

格式化和更新訊息

• 詳細報告（PDF）
• 市場預測模型（基於微軟Excel）
• 流行病學數據（MS Excel，互動式工具）
• 高階主管洞察（PPT簡報）
• 其他功能：定期更新、自訂和顧問支援。
• 根據 Thelansis 的政策，我們確保所有最新更新在發布前都反映在報告內容和市場模型中。

主要問題

• 如何最佳化 G8 市場（美國、歐盟 5 國、日本、中國）的藥物開發與生命週期管理策略？
• 從發病率、盛行率、人群組成以及接受藥物治療的患者人數來看，患者數量分別是多少？
• 未來十年市場收入和病患佔有率的預測是多少？
• 哪些因素對市場趨勢影響最大？
• 受訪專家對目前和新興的治療方法有何看法？
• 哪款在研發線產品最有前景？其上市潛力及未來市場定位如何？
• 主要未被滿足的需求是什麼？ KOL 對目標受眾有何期望？
• 為確保藥物獲得批准並順利進入市場，必須滿足哪些關鍵的監管和支付方要求？

目標國家

• G8
  • 美國
  • EU5
    • 法國
    • 德國
    • 義大利
    • 西班牙
    • 英國
  • 日本
  • 中國

大公司

• Pfizer
• ModernaTX, Inc.
• Tarsus Pharmaceuticals, Inc.
• Biocodex

目錄

第1章：主要調查結果和分析師說明

• 主要趨勢：市場概況、SWOT分析、商業性利益與風險等。

第2章：疾病背景

• 疾病定義、分類、病因和病理生理學、藥物標靶等。

第3章：流行病學

• 重點
• 發病率/盛行率
• 已確診並正在接受藥物治療的患者族群。
• 合併症
• 其他相關患者群

第4章 市場規模及預測

• 重點
• 市場促進因素與限制因素
• 按藥物類別分類的趨勢
• 各國具體趨勢

第5章 競爭情勢

• 目前的治療方法
• 重點
• 診斷和治療過程/演算法
• 目前主要療法－概述及關鍵意見領袖見解
• 新興療法
• 重點
• 值得關注的後期新興療法—概述、市場上市預期和關鍵意見領袖見解
• 值得關注的早期研發管線

第6章：未滿足的需求與目標產品分析

• 尚未滿足的主要需求及其透過新興療法實現的潛力。
• TPP分析與KOL展望

第7章 監理與報銷環境

第8章附錄

Lyme Disease Market Outlook

Thelansis's "Lyme Disease Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report - 2025 To 2035" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Lyme Disease treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Lyme Disease Overview

Lyme disease, caused by Borrelia burgdorferi transmitted through Ixodes tick bites, remains the most prevalent vector-borne illness across North America and Europe, with incidence climbing due to climate-driven tick range expansion. Diagnosis relies on clinical presentation and two-tier serology, while early-stage infection is typically curable with doxycycline or amoxicillin; however, delayed treatment can progress to debilitating neurological, cardiac, and arthritic complications, and post-treatment Lyme disease syndrome remains poorly understood. Pfizer and Valneva's investigational vaccine candidate PF-07307405 (LB6V, formerly VLA15) demonstrated 73-75% efficacy in the Phase 3 VALOR trial announced in March 2026, with regulatory submissions to the FDA and EMA planned this year, positioning it as the first prophylactic option since LYMErix's 2002 withdrawal and a major commercial catalyst.

Key Highlights

• In Germany, incident Lyme disease cases are projected to increase from 56,330 in 2025 to 57,357 by 2035.
• Lyme disease is the most common tick-borne bacterial infection, with early diagnosis being critical to prevent long-term complications.
• Delayed or inadequate treatment may lead to persistent neurological, cardiac, and musculoskeletal manifestations.
• Significant unmet need remains for improved diagnostics and therapies for persistent or difficult-to-treat disease.

Market Overview

• The France Lyme disease market is projected to grow from $70M in 2025 to $160M by 2035.
• Market growth is driven by:
• Increasing disease awareness and improved diagnostic testing
• Ongoing development of novel anti-infective therapies and vaccines
• Future growth will depend on advancements in early diagnosis, preventive strategies, and more effective treatment options.

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support
• As per Thelansis's policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2025-2035)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market's trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?

Countries Covered

• G8
  • United States
  • EU5
    • France
    • Germany
    • Italy
    • Spain
    • U.K.
  • Japan
  • China

Apart from the G8 Market, adding any additional country data to the dashboard will cost USD 1,750 per country

Companies Mentioned

• Pfizer
• ModernaTX, Inc.
• Tarsus Pharmaceuticals, Inc.
• Biocodex

Table of Contents

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risks, etc.

2. Disease Context

• Disease definition, classification, etiology and pathophysiology, drug targets, etc.

3. Epidemiology

• Key takeaways
• Incidence / Prevalence
• Diagnosed and Drug-Treated populations
• Comorbidities
• Other relevant patient segments

4. Market Size and Forecast

• Key takeaways
• Market drivers and constraints
• Drug-class specific trends
• Country-specific trends

5. Competitive Landscape

• Current therapies
• Key takeaways
• Dx and Tx journey/algorithm
• Key current therapies - profiles and KOL insights
• Emerging therapies
• Key takeaways
• Notable late-phase emerging therapies - profiles, launch expectations, KOL insights
• Notable early-phase pipeline

6. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

7. Regulatory and Reimbursement Environments (by country and payer insights)

8. Appendix (e.g., bibliography, methodology)